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Supplementary Methods 25 
Histological analysis and immunohistochemistry 26 
Three or four weeks after BMT, extra-orbital lacrimal glands, the proximal part of small 27 
intestine, dorsum skin, liver, salivary glands, lung, large intestine and eyes were collected 28 
from the transplant recipients. These samples were subsequently fixed with 10% neutral-29 
buffered formalin and embedded in paraffin. The paraffin blocks were cut into 7m-thick 30 
sections, and then stained with (1) hematoxylin and eosin, (2) Mallory’s trichrome1, 2 and (3) 31 
antibodies used in this study. For immunohistochemical assays, paraffin was removed in the 32 
first instance, followed by the recovery of the antigens using either of the following 2 antigen 33 
retrieval methods. (A) To stain the sections with a CD45 antibody (30-F11, BD Pharmingen, 34 
San Jose, CA), they were immersed in the antigen retrieval solution (Target Retrieval 35 
Solution; Dako, Glostrup, Denmark) and then boiled with a microwave oven for 10 min. (B) 36 
In the case of multiple staining for CD68 (FA-11, AbD Serotec, Kidlington, UK) and CHOP 37 
(F-168, Santa Cruz Biotechnology, Santa Cruz, CA), the sections were soaked in the antigen 38 
retrieval solution (HistoVT One; Nakalai Tesque, Kyoto, Japan) and subsequently heated at 39 
90 °C for 40 min with a water bath. Next, the sections were blocked with 10% normal goat 40 
serum, and the reactions between the antigens in tissue sections and the primary antibodies 41 
were conducted at 4°Covernight. The sections were then treated with fluorophore-labelled 42 
secondary antibodies at RT for 45 minutes and mounted with an anti-fading mounting 43 
medium (Fluorescent Mounting Medium; Dako). Fluorescence images were taken with an 44 
LSM confocal microscope (Carl Zeiss, Jena, Germany). As for the counting of CD45+ cells, 45 
five areas of each tissue section were randomly photographed under 200X magnification, and 46 
the number of CD45+ cells in the individual images was subsequently determined. 47 
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 The following secondary antibodies were used in this study: goat anti-mouse IgG (H+L) 48 
secondary antibody, Alexa Fluor 488 conjugate (Molecular Probes, Eugene, OR) and goat 49 
anti-rat IgG (H+L) secondary antibody, Alexa Fluor 568 conjugate (Molecular Probes). With 50 
respect to isotype controls, rat IgG2b, κ (eB149/10H5, eBioscience, San Diego, CA), rat 51 
IgG2a (54447, R&D Systems, Minneapolis, MN) and rabbit IgG (Cell Signaling Technology, 52 
Danvers, MA) were utilized for CD45, CD68 and CHOP, respectively.  53 
Electron microscopy  54 
Transmission electron microscopic analysis was performed according to standard protocols. 55 
Tissues were collected from the murine lacrimal glands and small intestine, immediately 56 
fixed with 2.5% glutaraldehyde in 0.1 M phosphate buffer (pH 7.4) at 4ºC for 4 hours and 57 
washed three times with 0.1 M phosphate buffer. The samples were subsequently fixed again 58 
with 2% osmium tetroxide, dehydrated in a graded series of ethanol and 100% propylene 59 
oxide, and embedded in epoxy resin. One micrometer sections were made from the processed 60 
tissues and then stained with methylene blue. The thick sections were observed with a 61 
microscope to find parts which were suitable for preparation of ultrathin sections. The 62 
obtained sections were placed on mesh grids, stained with uranylacetate and lead citrate, and 63 
examined with an electron microscope (1230 EXII; JOEL, Tokyo, Japan). All electron 64 
micrographs were acquired with a bio scan camera (Gatan bio scan camera model 792, Tokyo, 65 
Japan). 66 
Immunoblotting analysis 67 
The tissues of interest were placed in Eppendorf tubes, and pre-cooled RIPA buffer was 68 
added to the tubes. The tissues were then homogenized using an electric homogenizer. After 69 
the samples were on ice for 1h, they were centrifuged at 15000 rpm at 4°Cfor 5 min. The 70 
supernatants were subsequently collected in fresh tubes on ice and used as cell lysates. An 71 
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equal amount of 5X Laemmli buffer was added to each cell lysate, followed by protein 72 
denaturation at 100°Cfor 5 min. Equal amounts of protein from each sample were loaded 73 
into the wells of SDS-PAGE gels and then resolved. The proteins were transferred from the 74 
gels to membranes at 15 V for 20 min. The membranes were blocked with 5% skim milk or 75 
5% BSA in 1 x TBST (a mixture of tris-buffered saline and tween 20) at RT for 1h. The 76 
membranes were then incubated with primary antibodies at 4°Covernight. The primary 77 
antibodies were diluted 1000 times with 5% skim milk or 5% BSA in 1 x TBST. After the 78 
primary antibody incubation, the membranes were washed with 1 x TBST (3 x 10 min), 79 
subjected to secondary antibody at RT for 1h and then washed with 1 x TBST (3 x 10 min) 80 
and 1 x TBS (2 x 10 min). The proteins of interest were visualized using either of the 81 
following two methods. (1) Colorimetric detection of the target proteins was conducted using 82 
BCIP/NBT substrate (Promega, WI). (2) Signals were developed with an enhanced 83 
chemoluminescence (ECL) detection reagent (GE Healthcare, Littlecalfont, UK), and the 84 
target proteins were subsequently visualized with a LAS 4000 mini chemiluminescence 85 
imaging system (Fujifilm/GE Healthcare). Densitometric analysis of the obtained protein 86 
bands was conducted by the use of the image processing software ImageJ.  The primary 87 
antibodies used in this experiment were as follows: GRP78 (Abcam, Cambridge, UK), 88 
phospho-PERK (Thr980, Cell Signaling Technology), PERK (C33E10, Cell Signaling 89 
Technology), phosphor-IRE1 (Thermo Fisher Sceientific, Waltham, MA), IRE1 (14C10 90 
Cell Signaling Technology), phosphor-eIF2 (119A11, Cell Signaling Technology), eIF2 91 
(Cell Signaling Technology), CHOP (9C8, Thermo Fisher Scientific), TXNIP (D5F3E, Cell 92 
Signaling Technology) NF-B (Abcam), HSP47 (SPA-470, Stress Gen Biotechnologies Corp, 93 
San Diego, CA), CTGF (Abcam), -SMA (1A4, Abcam), CD68 (FA-11, Abcam), 94 
Cytokeratin (C-11, Abcam), CD3 (Abcam), CD19 (Cell Signaling Technology), CD20 (D-10, 95 
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Santa Cruz) and -actin (AC-15, Abcam). With regards to the secondary antibodies, (1) when 96 
the protein bands were visualized by developing a color, either an AP-conjugated anti-mouse 97 
IgG antibody (Promega), an AP-conjugated anti-rabbit IgG antibody (Promega) or AP-98 
conjugated anti-rat IgG antibody (Promega) was used, and (2) either an HRP-conjugated anti-99 
mouse antibody (Thermo Fisher Scientific) or an HRP-conjugated anti-rabbit antibody 100 
(Thermo Fisher Scientific) was required to detect the target proteins by ECL. 101 
Enzyme linked immunosorbent assay (ELISA) 102 
Blood was collected from PBA- and vehicle-medicated mice and subsequently centrifuged at 103 
4000 rpm for 10 min. The levels of MCP-1, tumor necrosis factor- (TNF- and interferon-104 
 (IFN- in the obtained sera were measured utilizing ELISA sets (Becton Dickinson). These 105 
assays were conducted according to the protocols provided by the manufacturer Becton 106 















Supplementary figures 120 
 121 
Supplementary Figure 1. Structures of the ER stress reducers (A) 4-phenylbutyric acid 122 













Supplementary Figure 2.  Suppression of cGVHD-caused ER stress by PBA. (A) 132 
Immunoblot assays of ER stress markers and the associated inflammatory molecules in 133 
cGVHD target organs. (Lanes 1, 3, 5: PBA-medicated organs. Lanes 2, 4, 6: Vehicle-134 
medicated organs) Cropped blots are displayed. (B) The target proteins in each organ were 135 
subsequently quantified by densitometry. PBA-treated organs (blue) and vehicle-treated 136 
organs (red). Data from one of two similar experiments are shown. The data are presented as 137 




























Supplementary Figure 3. Mitigation of cGVHD-elicited systemic inflammation and 162 
fibrosis using the ER stress mitigator PBA. (A) HE pictures of the PBA-treated organs and 163 
those treated with the solvent-vehicle. The images were taken at 200x magnification, and the 164 
scale bar is 200 m. Severely inflamed portions are shown with asterisks. In the pictures of 165 
the vehicle-medicated eye, an ellipse is placed where its meibomian glands were decreased 166 
and shrunk, and conjunctival epithelia are indicated with arrows. (B) Immunostaining for the 167 
generic leukocyte marker CD45 in the PBA-medicated tissues and their vehicle-medicated 168 
equivalents. CD45+ cells and cell nuclei were stained red and blue, respectively. The images 169 
were taken at 200x magnification, and the scale bar is 20 m. (C) Mallory’s staining for the 170 
PBA-injected organs and their vehicle-injected counterparts. The photographs were taken at 171 
200x magnification, and the scale bar is 200 m. Aberrantly fibrotic areas are shown with 172 
white asterisks. (D) The density of CD45+ cells in the PBA-treated and their vehicle-treated 173 
counterparts. PBA-treated organs (blue) and vehicle-treated organs (red). Data from one of 174 
two similar experiments are shown. The data are presented as means, ± SD, PBA n=3, 175 











Supplementary Figure 4. Protection of intestinal and conjunctival goblet cells by the ER 185 
stress attenuator PBA.  (A) PAS staining for the PBA-medicated small intestine and eyes 186 
and their vehicle-medicated counterparts. Purple dots in the pictures are goblet cells. The 187 
images were taken at 200x magnification, and the scale bar is 200 m. (B) The density of 188 
goblet cells in the PBA-treated small intestine and eyes (blue), and their vehicle-treated 189 
counterparts (red). The values are presented as means, ± SD, PBA: n=3, Vehicle: n=3 (small 190 




Supplementary Figure 5. Reduction of fibrotic indicators utilizing the ER stress 193 
alleviator PBA (A) Immunoblot analysis of the fibrotic marker CTGF. (Lanes 1, 3, 5: PBA-194 
treated organs, Lanes 2, 4, 6: vehicle-treated organs) Cropped blots are displayed. (B) The 195 
subsequent densitometric analysis of CTGF in each organ. PBA-treated organs (blue) and 196 
vehicle-treated organs (red). Data from one of two similar experiments are shown. The data 197 







Supplementary Figure 6. Full-length gels from immunoblot assays for the ER stress 203 
markers and inflammation-associated molecules shown in Figure 1B. Lanes 1, 3, 5, 7: 204 
Syngeneic control subjects, Lanes 2, 4, 6, 8: cGVHD-impaired organs. (A) GRP78, (B) 205 






Supplementary Figure 7. Full-length gels from immunoblot assays for the ER stress 210 
markers and inflammation-associated molecules shown in Figure 2A. Lanes 1, 3, 5, 7: 211 
PBA-medicated organs. Lanes 2, 4, 6, 8: Vehicle-medicated organs. (A) GRP78, (B) CHOP, 212 




Supplementary Figure 8. Full-length gels from immunoblot assays for the ER stress 215 
markers and inflammation-associated molecules shown in Supplementary Figure 2A. 216 
Lanes 1, 3, 5: PBA-medicated organs. Lanes 2, 4, 6: Vehicle-medicated organs. (A) GRP78, 217 




Supplementary Figure 9. Full-length gel from immunoblot analysis of the fibrotic 220 
marker CTGF shown in Figure 4B. Lanes 1, 3, 5, 7: PBA-medicated organs. Lanes 2, 4, 6, 221 
8: Vehicle-medicated organs.  222 
 223 
 224 
Supplementary Figure 10. Full-length gel from immunoblot analysis of the fibrotic 225 
marker CTGF shown in Supplementary Figure 5A. Lanes 1, 3, 5: PBA-medicated organs. 226 






Supplementary Figure 11. Full-length gels from immunoblot assays for the ER stress, 231 
activation and fibrotic markers shown in Figure 5A. (Lanes 1, 2, 3, 4: Fibroblasts from the 232 
PBA-treated lacrimal glands, Lanes 5, 6, 7, 8: Fibroblasts from the vehicle-treated lacrimal 233 






Supplementary Figure 12. Full-length gels from immunoblot assays for the ER stress 238 
markers shown in Figure 6C. Lanes 1, 2, 3, 4: Splenic macrophages from PBA-dosed mice, 239 
Lanes 5, 6, 7, 8: Splenic macrophages from vehicle-dosed mice). (A) GRP78, (B) CHOP, (C) 240 





Supplementary Figure 13. Full-length gels from immunoblot assays for -SMA and 244 
cytokeratin. (Lanes 1, 2, 3, 4: Fibroblasts from the PBA-treated lacrimal glands, Lanes 5, 6, 245 







Supplementary Figure 14. Full-length gels from immunoblot assays for CD68, CD3, 251 
CD19 and CD20. Lanes 1, 2, 3, 4: Splenic macrophages from PBA-dosed mice, Lanes 5, 6, 7, 252 
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